Phase 2 Sleep Disorders Trial, Recruiting NCT06434571 Sponsor: University of Kansas Medical Center Condition: Sleep Disorders
Back to Sleep Disorders

Phase 2 Sleep Disorders Trial, Recruiting

NCT06434571
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People between 18 and 65 years old
  • People who have been diagnosed with relapsing-remitting or secondary progressive MS, confirmed by their neurologist
  • People with mild-to-moderate disability, scoring 6 or below on a scale called the Patient Determined Disability Steps (PDDS)
  • People who have had trouble falling asleep, staying asleep, or waking up too early at least 3 nights per week for the past 3 months, where this causes real distress or affects daily life, and where there is enough opportunity for sleep
  • People who score 10 or higher on a standard sleep questionnaire called the Insomnia Severity Index
  • People who speak English
  • People who score 31 or higher on a telephone-based thinking and memory test
  • People who have a high school diploma or equivalent (used as a measure of reading ability)
  • People who have access to the internet or a mobile data plan, and who have access to a computer, tablet, or smartphone

Who may not be able to join:

  • People with a known sleep disorder that is not being treated, such as sleep apnea or restless legs syndrome
  • People whose answers on a screening tool called STOP BANG suggest a higher risk of sleep apnea (scoring more than 3)
  • People identified as having restless legs syndrome based on a specific diagnostic checklist
  • People identified as having a body-clock-related sleep disorder, based on a sleep disorders questionnaire
  • People identified as having a parasomnia (such as sleepwalking), based on a sleep disorders questionnaire
  • People currently taking certain sleep medications — such as benzodiazepines, related sleep drugs, or melatonin — for less than 3 months, or whose dose of these medications has changed in the past 3 months
  • People scoring 20 or higher on a depression questionnaire (PHQ-9), or who have indicated any level of thoughts of self-harm on that questionnaire
  • People scoring 15 or higher on an anxiety questionnaire (GAD-7)
  • People with a current or recent history (within the past 2 years) of alcohol or drug misuse, as defined by standard diagnostic guidelines
  • People with a history of another nervous system condition, such as stroke or Parkinson's disease
  • People who are currently pregnant or planning to become pregnant in the next 6 months
  • People with a severe mental health condition such as schizophrenia or bipolar disorder
  • People with severe neurological or sensory difficulties that would significantly affect their ability to participate in the study
  • People who have had an MS relapse or used corticosteroid medication in the past 8 weeks
  • People who currently work overnight shifts — or have done so within the past 5 years — during the hours of midnight to 4am
  • People who are currently taking part in another behavioural sleep treatment program

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 913-945-7349

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
University of Kansas Medical Center
Registry
ClinicalTrials.gov
Start date
11 October 2024
Est. completion
31 July 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Insomnia Severity Index (ISI)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov